$172.950
-2.127 (-1.23%)收盘时
ICUI 资讯
ICUI 事件
Company Raises FY26 Adjusted EBITDA Outlook to $415M-$435M
Consensus $8.16. Raises FY26 adjusted EBITDA view to $415M-$435M from $400M-$430M. The company said, "For Fiscal Year 2026 the Company is updating its estimates of GAAP net income from a range of $26 million to $44 million to a range of $73 million to $83 million and GAAP diluted earnings per share from a range of $1.03 to $1.74 to a range of $2.89 to $3.29. The Company is updating the estimate of its full year 2026 guidance of Adjusted EBITDA from a range of $400 million to $430 million to a range of $415 million to $435 million and diluted earnings per share from a range of $7.75 to $8.45 to a range of $8.60 to $9.00."
ICU Medical Q2 Revenue Exceeds Expectations at $551.68M
Reports Q2 revenue $551.68M, consensus $534.21M. Vivek Jain, ICU Medical's Chief Executive Officer, said, "Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business."
ICU Medical Reports Q1 Revenue of $530.23M
Reports Q1 revenue $530.23M, consensus $531.12M. Vivek Jain, ICU Medical's Chief Executive Officer, said, "First quarter results were generally in line with our expectations."
Company Sees FY26 Adjusted EBITDA of $400M to $430M
Sees FY26 adjusted EBITDA $400M-$430M. The company said, "For fiscal year 2026 the Company estimates GAAP net income to be in the range of $26 million to $44 million and GAAP net earnings per share estimated to be in the range of $1.03 to $1.74. For the fiscal year 2026, the Company expects adjusted EBITDA to be in the range of $400 million to $430 million, and adjusted EPS to be in the range of $7.75 to $8.45."
ICU Medical Reports Q4 Revenue of $540.7M
Reports Q4 revenue $540.7M, consensus $541.2M. Vivek Jain, ICU Medical's CEO, said, "Fourth quarter results were generally in line with our expectations."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。